This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
6 - 8 June, 2023
Postillon Hotel AmsterdamDigital Experience: All Sessions Live-streamed 6-8 June, 2023

Volker Schellenberger, Ph.D.
Co-Founder, President and CTO at Amunix Pharmaceuticals

Profile

Volker Schellenberger co-founded Amunix in 2006 and served as Chief Scientific Officer. He is the lead inventor of the company’s XTEN as well as XPAT platforms of protease-activated T cell engagers. Since the acquisition of Amunix by Sanofi in 2022, Volker directs discovery at the Amunix team, which serves as center of excellence for conditionally activated biologics within Sanofi. Volker has over 25 years of industry experience in protein engineering and drug discovery. Prior to co-founding Amunix he served as head of Genencor’s protein engineering department.

Volker received his Ph.D. from Leipzig University (Germany) in 1986. He is author of over 40 scientific papers and inventor of more than 70 issued or pending patent applications. He is a recipient of the Karl Lohmann prize of the German Society of Biochemists.

Agenda Sessions

  • XTEN® Polypeptide-Masked Protease Activated T cell Engagers: XPAT® Proteins - A Novel Format to Mitigate the On-target, Off-tumor Problem

    14:35